An electrocardiogram-based AI algorithm for early detection of pulmonary hypertension.


Journal

The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460

Informations de publication

Date de publication:
27 Jun 2024
Historique:
received: 26 01 2024
accepted: 18 05 2024
medline: 28 6 2024
pubmed: 28 6 2024
entrez: 27 6 2024
Statut: aheadofprint

Résumé

Early diagnosis of pulmonary hypertension (PH) is critical for effective treatment and management. We aimed to develop and externally validate an artificial intelligence algorithm that could serve as a PH screening tool, based on analysis of a standard 12-lead electrocardiogram (ECG). The PH Early Detection Algorithm (PH-EDA) is a convolutional neural network developed using retrospective ECG voltage-time data, with patients classified as "PH-likely" or "PH-unlikely" (controls) based on right heart catheterisation or echocardiography. In total, 39 823 PH-likely patients and 219 404 control patients from Mayo Clinic were randomly split into training (48%), validation (12%), and test (40%) sets. ECGs taken within 1 month of PH diagnosis (diagnostic dataset) were used to train the PH-EDA at Mayo Clinic. Performance was tested on diagnostic ECGs within the test sets from Mayo Clinic (n=16 175/87 998 PH-likely/controls) and Vanderbilt University Medical Center (VUMC; n=6045/24 256 PH-likely/controls). Performance was also tested on ECGs taken 6-18 months (pre-emptive dataset), and up to 5 years prior to a PH diagnosis at both sites. Performance testing yielded an area under the receiver operating characteristic curve (AUC) of 0.92 and 0.88 in the diagnostic test set at Mayo Clinic and VUMC, respectively, and 0.86 and 0.81, respectively, in the pre-emptive test set. The AUC remained a minimum of 0.79 at Mayo Clinic and 0.73 at VUMC up to 5 years before diagnosis. The PH-EDA can detect PH at diagnosis and 6-18 months prior, demonstrating the potential to accelerate diagnosis and management of this debilitating disease.

Sections du résumé

BACKGROUND BACKGROUND
Early diagnosis of pulmonary hypertension (PH) is critical for effective treatment and management. We aimed to develop and externally validate an artificial intelligence algorithm that could serve as a PH screening tool, based on analysis of a standard 12-lead electrocardiogram (ECG).
METHODS METHODS
The PH Early Detection Algorithm (PH-EDA) is a convolutional neural network developed using retrospective ECG voltage-time data, with patients classified as "PH-likely" or "PH-unlikely" (controls) based on right heart catheterisation or echocardiography. In total, 39 823 PH-likely patients and 219 404 control patients from Mayo Clinic were randomly split into training (48%), validation (12%), and test (40%) sets. ECGs taken within 1 month of PH diagnosis (diagnostic dataset) were used to train the PH-EDA at Mayo Clinic. Performance was tested on diagnostic ECGs within the test sets from Mayo Clinic (n=16 175/87 998 PH-likely/controls) and Vanderbilt University Medical Center (VUMC; n=6045/24 256 PH-likely/controls). Performance was also tested on ECGs taken 6-18 months (pre-emptive dataset), and up to 5 years prior to a PH diagnosis at both sites.
RESULTS RESULTS
Performance testing yielded an area under the receiver operating characteristic curve (AUC) of 0.92 and 0.88 in the diagnostic test set at Mayo Clinic and VUMC, respectively, and 0.86 and 0.81, respectively, in the pre-emptive test set. The AUC remained a minimum of 0.79 at Mayo Clinic and 0.73 at VUMC up to 5 years before diagnosis.
CONCLUSION CONCLUSIONS
The PH-EDA can detect PH at diagnosis and 6-18 months prior, demonstrating the potential to accelerate diagnosis and management of this debilitating disease.

Identifiants

pubmed: 38936966
pii: 13993003.00192-2024
doi: 10.1183/13993003.00192-2024
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright ©The authors 2024. For reproduction rights and permissions contact permissions@ersnet.org.

Auteurs

Hilary M DuBrock (HM)

Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA dubrock.hilary@mayo.edu.
Co-first authors.

Tyler E Wagner (TE)

nference, Cambridge, MA, USA.
Anumana, Cambridge, MA, USA.
Co-first authors.

Katherine Carlson (K)

nference, Cambridge, MA, USA.
Anumana, Cambridge, MA, USA.

Corinne L Carpenter (CL)

nference, Cambridge, MA, USA.
At the time of study.

Samir Awasthi (S)

nference, Cambridge, MA, USA.
Anumana, Cambridge, MA, USA.

Zachi I Attia (ZI)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.

Robert P Frantz (RP)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.

Paul A Friedman (PA)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.

Suraj Kapa (S)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.

Jeffrey Annis (J)

Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Vanderbilt Institute for Clinical and Translational Research, Nashville, TN, USA.

Evan L Brittain (EL)

Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

Anna R Hemnes (AR)

Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

Samuel J Asirvatham (SJ)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.

Melwin Babu (M)

Anumana, Cambridge, MA, USA.
nference Labs, Bangalore, India.

Ashim Prasad (A)

Anumana, Cambridge, MA, USA.
nference Labs, Bangalore, India.

Unice Yoo (U)

nference, Cambridge, MA, USA.

Rakesh Barve (R)

Anumana, Cambridge, MA, USA.
nference Labs, Bangalore, India.

Mona Selej (M)

Janssen Research and Development, LLC, a Johnson and Johnson company.

Peter Agron (P)

Janssen Research and Development, LLC, a Johnson and Johnson company.

Emily Kogan (E)

Janssen Research and Development, LLC, a Johnson and Johnson company.

Deborah Quinn (D)

Janssen Research and Development, LLC, a Johnson and Johnson company.

Preston Dunnmon (P)

Janssen Research and Development, LLC, a Johnson and Johnson company.

Najat Khan (N)

Janssen Research and Development, LLC, a Johnson and Johnson company.
At the time of study.

Venky Soundararajan (V)

nference, Cambridge, MA, USA.
Anumana, Cambridge, MA, USA.

Classifications MeSH